Skip to main content
Top
Published in: Calcified Tissue International 6/2009

Open Access 01-06-2009

Surface Aggregation of Urinary Proteins and Aspartic Acid-Rich Peptides on the Faces of Calcium Oxalate Monohydrate Investigated by In Situ Force Microscopy

Authors: Matthew L. Weaver, S. Roger Qiu, John R. Hoyer, William H. Casey, George H. Nancollas, James J. De Yoreo

Published in: Calcified Tissue International | Issue 6/2009

Login to get access

Abstract

The growth of calcium oxalate monohydrate in the presence of Tamm-Horsfall protein (THP), osteopontin, and the 27-residue synthetic peptides (DDDS)6DDD and (DDDG)6DDD (D = aspartic acid, S = serine, and G = glycine) was investigated via in situ atomic force microscopy. The results show that these four growth modulators create extensive deposits on the crystal faces. Depending on the modulator and crystal face, these deposits can occur as discrete aggregates, filamentary structures, or uniform coatings. These proteinaceous films can lead to either the inhibition of or an increase in the step speeds (with respect to the impurity-free system), depending on a range of factors that include peptide or protein concentration, supersaturation, and ionic strength. While THP and the linear peptides act, respectively, to exclusively increase and inhibit growth on the \( \left( {\bar{1}01} \right) \) face, both exhibit dual functionality on the (010) face, inhibiting growth at low supersaturation or high modulator concentration and accelerating growth at high supersaturation or low modulator concentration. Based on analyses of growth morphologies and dependencies of step speeds on supersaturation and protein or peptide concentration, we propose a picture of growth modulation that accounts for the observations in terms of the strength of binding to the surfaces and steps and the interplay of electrostatic and solvent-induced forces at the crystal surface.
Literature
1.
go back to reference Fleming DE, Van Riessen A, Chauvet MC, Grover PK, Hunter B, Van Bronswijk W, Ryall RL (2003) Intracrystalline proteins and urolithiasis: a synchrotron X-ray diffraction study of calcium oxalate monohydrate. J Bone Miner Res 18(7):1282–1291PubMedCrossRef Fleming DE, Van Riessen A, Chauvet MC, Grover PK, Hunter B, Van Bronswijk W, Ryall RL (2003) Intracrystalline proteins and urolithiasis: a synchrotron X-ray diffraction study of calcium oxalate monohydrate. J Bone Miner Res 18(7):1282–1291PubMedCrossRef
2.
go back to reference Coe FL, Parks JH, Asplin JR (1992) The pathogenesis and treatment of kidney stones. N Engl J Med 327(16):1141–1152PubMedCrossRef Coe FL, Parks JH, Asplin JR (1992) The pathogenesis and treatment of kidney stones. N Engl J Med 327(16):1141–1152PubMedCrossRef
3.
go back to reference Dussol B, Geider S, Lilova A, Leonetti F, Dupuy P, Daudon M, Berland Y, Dagorn JC, Verdier JM (1995) Analysis of the soluble organic matrix of five morphologically different kidney stones: evidence for a specific role of albumin in the constitution of the stone protein matrix. Urol Res 23(1):45–51PubMedCrossRef Dussol B, Geider S, Lilova A, Leonetti F, Dupuy P, Daudon M, Berland Y, Dagorn JC, Verdier JM (1995) Analysis of the soluble organic matrix of five morphologically different kidney stones: evidence for a specific role of albumin in the constitution of the stone protein matrix. Urol Res 23(1):45–51PubMedCrossRef
4.
go back to reference Kurutz JW, Carvalho M, Nakagawa Y (2003) Nephrocalcin isoforms coat crystal surfaces and differentially affect calcium oxalate monohydrate crystal morphology, growth, and aggregation. J Cryst Growth 255(3–4):392–402CrossRef Kurutz JW, Carvalho M, Nakagawa Y (2003) Nephrocalcin isoforms coat crystal surfaces and differentially affect calcium oxalate monohydrate crystal morphology, growth, and aggregation. J Cryst Growth 255(3–4):392–402CrossRef
5.
go back to reference Wesson JA, Ganne V, Beshensky AM, Kleinman JG (2005) Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol Res 33(3):206–212PubMedCrossRef Wesson JA, Ganne V, Beshensky AM, Kleinman JG (2005) Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol Res 33(3):206–212PubMedCrossRef
6.
go back to reference Glauser A, Hochreiter W, Jaeger P, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 15(10):1580–1587PubMedCrossRef Glauser A, Hochreiter W, Jaeger P, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 15(10):1580–1587PubMedCrossRef
7.
go back to reference Shiraga H, Min W, VanDusen WJ et al (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89(1):426–430PubMedCrossRef Shiraga H, Min W, VanDusen WJ et al (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89(1):426–430PubMedCrossRef
8.
go back to reference Worcester EM, Nakagawa Y, Wabner CL, Kumar S, Coe FL (1988) Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol 255(6; Pt. 2):F1197–F1205PubMed Worcester EM, Nakagawa Y, Wabner CL, Kumar S, Coe FL (1988) Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol 255(6; Pt. 2):F1197–F1205PubMed
9.
go back to reference Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257(1;Pt. 2):F99–F106PubMed Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257(1;Pt. 2):F99–F106PubMed
10.
go back to reference Hess B, Zipperle L, Jaeger P (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265(62):784–791 Hess B, Zipperle L, Jaeger P (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265(62):784–791
11.
go back to reference Kumar V, Farell G, Lieske John C (2003) Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells. J Urol 170(1):221–225PubMedCrossRef Kumar V, Farell G, Lieske John C (2003) Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells. J Urol 170(1):221–225PubMedCrossRef
12.
go back to reference Kumar V, Pena de la Vega L, Farell G, Lieske John C (2005) Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int 68(4):1784–1792PubMedCrossRef Kumar V, Pena de la Vega L, Farell G, Lieske John C (2005) Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int 68(4):1784–1792PubMedCrossRef
13.
go back to reference Worcester EM (1994) Urinary calcium oxalate crystal growth inhibitors. J Am Soc Nephrol 5(5):S46–S53PubMed Worcester EM (1994) Urinary calcium oxalate crystal growth inhibitors. J Am Soc Nephrol 5(5):S46–S53PubMed
14.
go back to reference Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, Zepeda S, De Yoreo JJ (2004) Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 101(7):1811–1815PubMedCrossRef Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, Zepeda S, De Yoreo JJ (2004) Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 101(7):1811–1815PubMedCrossRef
15.
go back to reference Ryall RL, Phulwinder KG, Thurgod LA, Chauvet MC, Fleming DE, van Bronswijk W (2007) The importance of a clean face: the effect of different washing procedures on the association of Tamm-Horsfall glycoprotein and other urinary proteins with calcium oxalate crystals. Urol Res 35(1):1–14 Ryall RL, Phulwinder KG, Thurgod LA, Chauvet MC, Fleming DE, van Bronswijk W (2007) The importance of a clean face: the effect of different washing procedures on the association of Tamm-Horsfall glycoprotein and other urinary proteins with calcium oxalate crystals. Urol Res 35(1):1–14
16.
go back to reference Sheng X, Jung T, Wesson JA, Ward MD (2005) Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci USA 102(2):267–272PubMedCrossRef Sheng X, Jung T, Wesson JA, Ward MD (2005) Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci USA 102(2):267–272PubMedCrossRef
17.
go back to reference Hoyer JR, Asplin JR, Otvos L Jr (2001) Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60(1):77–82PubMedCrossRef Hoyer JR, Asplin JR, Otvos L Jr (2001) Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60(1):77–82PubMedCrossRef
18.
go back to reference Fields GB, Noble RL (1990) Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35(3):161–214PubMed Fields GB, Noble RL (1990) Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35(3):161–214PubMed
19.
go back to reference Hoyer JR, Otvos L Jr, Urge L (1995) Osteopontin in urinary stone formation. Ann N Y Acad Sci 760:257–265PubMedCrossRef Hoyer JR, Otvos L Jr, Urge L (1995) Osteopontin in urinary stone formation. Ann N Y Acad Sci 760:257–265PubMedCrossRef
20.
go back to reference Bleyer AJ, Hart TC, Shihabi Z, Robins V, Hoyer JR (2004) Mutations in the uromodulin gene decrease urinary excretion of Tamm-Horsfall protein. Kidney Int 66(3):974–977PubMedCrossRef Bleyer AJ, Hart TC, Shihabi Z, Robins V, Hoyer JR (2004) Mutations in the uromodulin gene decrease urinary excretion of Tamm-Horsfall protein. Kidney Int 66(3):974–977PubMedCrossRef
21.
go back to reference Tamm I, Horsfall FL Jr (1950) Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med 74:108–114 Tamm I, Horsfall FL Jr (1950) Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med 74:108–114
22.
go back to reference Fontan E, Briend E, Saklani-Jusforgues H, D’Alayer J, Vandekerckhove J, Fauve RM (1994) A 92-kDa human immunostimulatory protein. Proc Natl Acad Sci USA 91(18):8353–8357PubMedCrossRef Fontan E, Briend E, Saklani-Jusforgues H, D’Alayer J, Vandekerckhove J, Fauve RM (1994) A 92-kDa human immunostimulatory protein. Proc Natl Acad Sci USA 91(18):8353–8357PubMedCrossRef
23.
go back to reference Hession C, Decker JM, Sherblom AP, Kumar S, Yue CC, Mattaliano RJ, Tizard R, Kawashima E, Schmeissner U (1987) Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science 237(4821):1479–1484PubMedCrossRef Hession C, Decker JM, Sherblom AP, Kumar S, Yue CC, Mattaliano RJ, Tizard R, Kawashima E, Schmeissner U (1987) Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science 237(4821):1479–1484PubMedCrossRef
24.
go back to reference Cody AM, Horner HT, Cody RD (1982) SEM study of the fine surface features of synthetic calcium oxalate monohydrate crystals. Scan Electron Microsc 1982(1):185–197 Cody AM, Horner HT, Cody RD (1982) SEM study of the fine surface features of synthetic calcium oxalate monohydrate crystals. Scan Electron Microsc 1982(1):185–197
25.
go back to reference Tomazic BB, Nancollas GH (1979) A study of the phase transformation of calcium oxalate trihydrate monohydrate. Investig Urol 16(5):329–335 Tomazic BB, Nancollas GH (1979) A study of the phase transformation of calcium oxalate trihydrate monohydrate. Investig Urol 16(5):329–335
26.
go back to reference Gilmer GH, Ghez R, Cabrera N (1971) Analysis of combined surface and volume diffusion processes in crystal growth. J Cryst Growth 8(1):79–93CrossRef Gilmer GH, Ghez R, Cabrera N (1971) Analysis of combined surface and volume diffusion processes in crystal growth. J Cryst Growth 8(1):79–93CrossRef
27.
go back to reference Land TA, De Yoreo JJ, Lee JD (1997) An in situ AFM investigation of canavalin crystallization kinetics. Surf Sci 384(1–3):136–155CrossRef Land TA, De Yoreo JJ, Lee JD (1997) An in situ AFM investigation of canavalin crystallization kinetics. Surf Sci 384(1–3):136–155CrossRef
28.
go back to reference Wang L, Qiu SR, Zachowicz W, Guan X, De Yoreo JJ, Nancollas GH, Hoyer JR (2006) Constant composition studies verify the utility of the Cabrerea Vermilyea (C-–V) in explaining mechanisms of calcium oxalate monohydrate crystallization. Langmuir 22:7279–7285PubMedCrossRef Wang L, Qiu SR, Zachowicz W, Guan X, De Yoreo JJ, Nancollas GH, Hoyer JR (2006) Constant composition studies verify the utility of the Cabrerea Vermilyea (C-–V) in explaining mechanisms of calcium oxalate monohydrate crystallization. Langmuir 22:7279–7285PubMedCrossRef
29.
go back to reference De Yoreo JJ, Vekilov PG (2003) Principles of crystal nucleation and growth. Rev Mineral Geochem (Biomineralization) 54:57–93CrossRef De Yoreo JJ, Vekilov PG (2003) Principles of crystal nucleation and growth. Rev Mineral Geochem (Biomineralization) 54:57–93CrossRef
30.
go back to reference Weaver ML, Qiu SR, Hoyer JR, Casey WH, Nancollas GH, De Yoreo JJ (2007) Inhibition of calcium oxalate monohydrate growth by citrate and the effect of the background electrolyte. J Cryst Growth 306:133–145CrossRef Weaver ML, Qiu SR, Hoyer JR, Casey WH, Nancollas GH, De Yoreo JJ (2007) Inhibition of calcium oxalate monohydrate growth by citrate and the effect of the background electrolyte. J Cryst Growth 306:133–145CrossRef
31.
go back to reference Elhadj S, De Yoreo JJ, Hoyer JR, Dove PM (2006) Role of molecular charge and hydrophilicity in regulating the kinetics of crystal growth. Proc Natl Acad Sci USA 103(51):19237–19242PubMedCrossRef Elhadj S, De Yoreo JJ, Hoyer JR, Dove PM (2006) Role of molecular charge and hydrophilicity in regulating the kinetics of crystal growth. Proc Natl Acad Sci USA 103(51):19237–19242PubMedCrossRef
32.
go back to reference Land TA, De Yoreo JJ (2000) The evolution of growth modes and activity of growth sources on canavalin investigated by in situ atomic force microscopy. J Cryst Growth 208(1–4):623–637CrossRef Land TA, De Yoreo JJ (2000) The evolution of growth modes and activity of growth sources on canavalin investigated by in situ atomic force microscopy. J Cryst Growth 208(1–4):623–637CrossRef
33.
go back to reference De Yoreo JJ, Qiu SR, Hoyer JR (2006) Molecular modulation of calcium oxalate crystallization. Am J Physiol 291(6, Pt. 2):F1123–F1131 De Yoreo JJ, Qiu SR, Hoyer JR (2006) Molecular modulation of calcium oxalate crystallization. Am J Physiol 291(6, Pt. 2):F1123–F1131
34.
go back to reference Weaver M, Qiu SR, Hoyer JH, Casey WH, Nancollas GH, De Yoreo JJ (2006) Improved model for inhibition of pathological mineralization based on citrate-calcium oxalate monohydrate interaction. ChemPhysChem 7:2081–2084PubMedCrossRef Weaver M, Qiu SR, Hoyer JH, Casey WH, Nancollas GH, De Yoreo JJ (2006) Improved model for inhibition of pathological mineralization based on citrate-calcium oxalate monohydrate interaction. ChemPhysChem 7:2081–2084PubMedCrossRef
35.
go back to reference Cabrera N, Vermilyea DA (1958) Growth of crystals from solution. In: Growth and perfection of crystals, proceedings of the international conference, Cooperstown, NY, pp 393–410 Cabrera N, Vermilyea DA (1958) Growth of crystals from solution. In: Growth and perfection of crystals, proceedings of the international conference, Cooperstown, NY, pp 393–410
36.
go back to reference Chernov AA (1984) Modern crystallography III: crystal growth. In: Cardona M, Fulde P, Queisser HJ (eds) Springer series in solid state sciences. Springer, Berlin Chernov AA (1984) Modern crystallography III: crystal growth. In: Cardona M, Fulde P, Queisser HJ (eds) Springer series in solid state sciences. Springer, Berlin
37.
go back to reference Elhadj S, Salter EA, Wierzbicki A, De Yoreo JJ, Han N, Dove PM (2006) Peptide controls on calcite mineralization: polyaspartate chain length affects growth kinetics and acts as a stereochemical switch on morphology. Cryst Growth Des 6(1):197–201CrossRef Elhadj S, Salter EA, Wierzbicki A, De Yoreo JJ, Han N, Dove PM (2006) Peptide controls on calcite mineralization: polyaspartate chain length affects growth kinetics and acts as a stereochemical switch on morphology. Cryst Growth Des 6(1):197–201CrossRef
38.
go back to reference Piana S, Jones F, Gale JD (2007) Aspartic acid as a crystal growth catalyst. CrystEngComm 9(12):1187–1191CrossRef Piana S, Jones F, Gale JD (2007) Aspartic acid as a crystal growth catalyst. CrystEngComm 9(12):1187–1191CrossRef
39.
40.
go back to reference Cheng Z, Russel WB, Chaikin PM (1999) Controlled growth of hard-sphere colloidal crystals. Nature 401(6756):893–895CrossRef Cheng Z, Russel WB, Chaikin PM (1999) Controlled growth of hard-sphere colloidal crystals. Nature 401(6756):893–895CrossRef
41.
go back to reference Van Blaaderen A (2004) Colloids under external control. MRS Bull 29(2):85–90 Van Blaaderen A (2004) Colloids under external control. MRS Bull 29(2):85–90
Metadata
Title
Surface Aggregation of Urinary Proteins and Aspartic Acid-Rich Peptides on the Faces of Calcium Oxalate Monohydrate Investigated by In Situ Force Microscopy
Authors
Matthew L. Weaver
S. Roger Qiu
John R. Hoyer
William H. Casey
George H. Nancollas
James J. De Yoreo
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 6/2009
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-009-9223-0

Other articles of this Issue 6/2009

Calcified Tissue International 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine